TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB21047

Activity

Antibacterial Anticancer Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

Peptipedia PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 20-aa standard natural multi-activity (Antibacterial, Anticancer, Hemolysis, and other sources) peptide sequence curated from Peptipedia and PD_Hemolysis, with an available 3D structural model.

Sequence

HIFKKVKTYWKKLFRILGRF

FASTA

>TPDB21047|Antibacterial;Anticancer;Hemolysis;Toxicity|length=20
HIFKKVKTYWKKLFRILGRF

Formula C130H202N34O23

Absent Amino Acids ANDCEQMPS

Common Amino Acids K

Mass 2609.25

PI 11.70

Basic Residues 8

Acidic Residues 0

Hydrophobic Residues 10

Net Charge +7

Boman Index -0.17

Hydrophobicity -0.290

Aliphatic Index 92.50

Half Life

Mammalian: 3.5 hour Yeast: 10 min E.coli: >10 hour

Extinction Coefficient Cystines 6990

Absorbance 280nm 267.89

Polar Residues 2

number

0

A

2

R

0

N

0

D

0

C

0

E

0

Q

1

G

1

H

2

I

2

L

5

K

0

M

3

F

0

P

0

S

1

T

1

W

1

Y

1

V

Amino Acid Distribution

A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 2 L: 2 K: 5 M: 0 F: 3 P: 0 S: 0 T: 1 W: 1 Y: 1 V: 1

Length

20

Formula

C130H202N34O23

Mass

2609.25

PI

11.70

Net Charge

+7

Boman Index

-0.17

Hydrophobicity

-0.290

Evidence 1 Activity

Activity

Activity Endpoint HC50

Detail Source Activity Hemolysis

Activity Measurement 16

Hemolysis Raw

Human erythrocytes: HC50=16 ± 2 µM

Target

RBC Target Human erythrocytes

Source & Reference

Database Source Hemolytik PD_Hemolysis

Source DRAMP4

Reference

Sci Rep. 2019 Aug 2 9(1):11282.

Other

Source Activity Label	Source Definition
Hemolysis	Hemolytik experimentally validated hemolytic peptide annotation.

Evidence 2 Activity

Activity

Activity Endpoint EC50

Detail Source Activity Toxicity

Activity Measurement 5.0±0.7 µM

Toxicity Type Cytotoxic

Toxicity Raw

EC50 | 5.0±0.7 | µM | target cell: Human dermal microvascular endothelial cells HDME

Target

Target Cell Human dermal microvascular endothelial cells HDME

Source & Reference

Database Source NA

Source Database DBAASP

Reference

In silico design and optimization of selective membranolytic anticancer peptides. | Sci Rep | 2019

Evidence 3 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 16±2 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | 16±2 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

In silico design and optimization of selective membranolytic anticancer peptides. | Sci Rep | 2019

Evidence 4 Activity

Activity

Activity Endpoint HC50

Detail Source Activity Toxicity

Activity Measurement 16

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

Hemolytic_activity: Human erythrocytes: HC50=16 ± 2 µM | Cytotoxicity: HDMEC: EC50=5.0 ± 0.7 µM

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Sci Rep. 2019 Aug 2 9(1):11282.

Evidence 5 Hemolysis

Activity

Activity Measurement 16

Activity Endpoint HC50

Hemolysis Raw

Human erythrocytes: HC50=16 ± 2 µM

Detail Source Activity Hemolysis

Target

RBC Target Human erythrocytes

Source & Reference

source PD_Hemolysis

Reference

Sci Rep. 2019 Aug 2 9(1):11282.

Source DRAMP4

Database Source PD_Hemolysis